Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

NCT03304054 is registered in ClinicalTrials.gov with Catalyst Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03304054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03304054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 18, 2018
Completion date
March 15, 2020
Enrollment
93 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, generalized